23.99
+0.27(+1.14%)
Currency In USD
| Previous Close | 23.72 |
| Open | 23.69 |
| Day High | 24.13 |
| Day Low | 23.25 |
| 52-Week High | 25.77 |
| 52-Week Low | 3.5 |
| Volume | 1.39M |
| Average Volume | 1.56M |
| Market Cap | 1.56B |
| PE | 74.97 |
| EPS | 0.32 |
| Moving Average 50 Days | 16.23 |
| Moving Average 200 Days | 8.27 |
| Change | 0.27 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $1,132.67 as of January 14, 2026 at a share price of $23.99. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $3,044.42 as of January 14, 2026 at a share price of $23.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
GlobeNewswire Inc.
Jan 09, 2026 3:49 AM GMT
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwri
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 07, 2026 9:01 PM GMT
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an u
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inf